The Human Genome Diversity Project was an important controversial research program arising from the debates surrounding the mapping of the human genome. This book, based on a detailed ethnographic study of two laboratories involved in the project, explores issues concerning standardization, naturalization and diversity generated in day-to-day work by scientists and technicians.

This work explores the way changes in technology have affected the relationship between ethics and medicine, generating new approaches to ethical issues and the implications of medical practice. Drawing on extensive ethnographic research with families affected by Huntington's Disease, Monica Konrad explores the huge disparity between the experience of living with the results of genetic testing and the knowledge and expertise to develop policy, clinical services and support.

This book applies a social science perspective to an examination of issues that arise in clinical practice as a result of drug development linked to genetic testing. These include the social context within which new drugs undergo trials and the related attitudes and expectations of clinicians and patients. Two case studies illustrate the arguments--one on aspects of Alzheimer's disease, and the other on the drug Herceptin which is used in the treatment of breast cancer.

The Human Genome Diversity Project was an important controversial research program arising from the debates surrounding the mapping of the human genome. This book, based on a detailed ethnographic study of two laboratories involved in the project, explores issues concerning standardization, naturalization and diversity generated in day-to-day work by scientists and technicians.

This work explores the way changes in technology have affected the relationship between ethics and medicine, generating new approaches to ethical issues and the implications of medical practice. Drawing on extensive ethnographic research with families affected by Huntington's Disease, Monica Konrad explores the huge disparity between the experience of living with the results of genetic testing and the knowledge and expertise to develop policy, clinical services and support.

This book applies a social science perspective to an examination of issues that arise in clinical practice as a result of drug development linked to genetic testing. These include the social context within which new drugs undergo trials and the related attitudes and expectations of clinicians and patients. Two case studies illustrate the arguments--one on aspects of Alzheimer's disease, and the other on the drug Herceptin which is used in the treatment of breast cancer.